Clinical trials: Usual Interstitial Pneumonia, active
Pulmonary Fibrosis
Genetic Polymorphisms in Idiopathic Pulmonary Fibrosis (IPF)
The purposes of this study are: to determine if there are specific genetic traits that might explain why patients have developed pulmonary fibrosis; to determine if specific genetic traits account for differing patterns of…
- Trial name
- GP (NCT00258570)
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- University of Pittsburgh
Idiopathic Pulmonary Fibrosis
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
This is a Ph 2, randomized, double-blind, placebo-controlled global multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of PIPE-791 in participants with a diagnosis of Idiopathic Pulmonary…
- Trial name
- NCT07284459
- Testing
- PIPE-791 Dose A, PIPE-791 Dose B
- Where
- 108 sites in Argentina, Australia and 17 more
- Volunteers
- 324 people
- Sponsor
- Contineum Therapeutics
Pulmonary Fibrosis, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease
This study will investigate whether the senicapoc drug can prevent the scarring from worsening in interstitial lung disease. Researchers will compare Senicapoc to a placebo (a look-alike substance that contains no drug) to see if…
- Trial name
- FIBROPOC (NCT06714123)
- Testing
- Senicapoc
- Where
- 5 sites in Denmark, Estonia and 1 more
- Volunteers
- 140 people
- Sponsor
- Vejle Hospital
Idiopathic Pulmonary Fibrosis
Inspiratory Effort and Respiratory Mechanics in Spontaneously Breathing Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Matched Control Study
Idiopathic pulmonary fibrosis is a life-threatening lung disease characterized by progressive deterioration of lung function and a median survival time of 3-5 years from diagnosis.
- Trial name
- IERATIC (NCT05313672)
- Volunteers
- 20 people
- Sponsor
- Roberto Tonelli
Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Inspiratory Flow Rate Capability in Pulmonary Fibrosis Patients
The goal of this observational study is to learn about the inspiratory flow rate capability in patients with pulmonary fibrosis (IPF or PPF) when using inhaler devices with different resistances.
- Trial name
- NCT07820254
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Idiopathic Pulmonary Fibrosis, Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) are sudden and severe worsening episodes that can be life-threatening. Currently, no treatment has been proven to clearly improve outcomes during these events.
- Trial name
- MERCURION-IPF (NCT07299695)
- Testing
- Intravenous immunoglobulin (IVIG), Usual treatment
- Where
- Greece
- Volunteers
- 196 people
- Sponsor
- Argyrios Tzouvelekis
Idiopathic Pulmonary Fibrosis and Progressive Fibrotic Interstitial Lung Disease
Human Autologous Lung Stem Cell Transplant for Idiopathic Pulmonary Fibrosis
Purpose: To demonstrate the safety and efficacy of autologous Lung Spheroid Stem Cells (LSCs) administered by intravenous infusion in patients with idiopathic pulmonary fibrosis Progressive Fibrotic Interstitial Lung Disease.
- Trial name
- HALT-IPF (NCT04262167)
- Testing
- Lung Spheroid Stem Cells 100 million, Lung Spheroid Stem Cells 200 million
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of North Carolina, Chapel Hill
Idiopathic Pulmonary Fibrosis (IPF)
IPF Longitudinal Natural History Study
This is a longitudinal observational cohort study of patients with idiopathic pulmonary fibrosis (IPF) conducted within the Assiut University IPF Research Program between 2022 and 2026.
- Trial name
- NCT07560189
- Where
- Egypt
- Volunteers
- 1,423 people
- Sponsor
- Assiut University
Idiopathic Pulmonary Fibrosis
Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
The goal of this clinical trial is to learn if a clinical trial for idiopathic pulmonary fibrosis (IPF) can recruit and retain participants from their home to study whether a combination of zinc and nicotinamide riboside can…
- Trial name
- NCT06567717
- Testing
- Zinc, Nicotinamide riboside
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Cedars-Sinai Medical Center
Interstitial Lung Disease, Sarcoidosis
Interstitial Lung Disease Research Unit Biobank
Establish a interstitial lung disease (ILD) registry and biorepository to lead towards a further understanding of the disease.
- Conditions
- Interstitial Lung Disease, Sarcoidosis, Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis
- Trial name
- ILDRU (NCT05392881)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- University of Kansas Medical Center
Idiopathic Pulmonary Fibrosis(IPF)
Jin-shui Huan-xian Formula for Retarding the Decline of Pulmonary Function in IPF
This study is to evaluate the clinical efficacy and safety of Jin-shui Huan-xian Formula in retarding the decline of pulmonary function in IPF, generate high - quality clinical evidence, and establish a treatment plan of Jin-shui…
- Trial name
- NCT06914713
- Testing
- Jin-shui Huan-xian granule
- Where
- China
- Volunteers
- 384 people
- Sponsor
- Henan University of Traditional Chinese Medicine
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Pilot Study of Nitrate-rich Beetroot Juice Supplementation in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic pulmonary fibrosis (IPF) is a type of scarring (fibrotic) lung disease. Reduced exercise capacity is a key symptom experienced by patients.
- Trial name
- BEET-IPF (NCT06488638)
- Testing
- nitrate-rich beetroot juice (70ml with approx. 400 mg nitrate) twice a day for 3 days
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Idiopathic Pulmonary Fibrosis
Daoyin Technique for Improving Exercise Endurance in IPF
This study is based on the previously constructed digital rehabilitation management platform, scientifically evaluating the clinical efficacy of guided technology in improving IPF exercise endurance, and forming high-quality…
- Trial name
- NCT07019714
- Testing
- Daoyin Technique, Routine Comprehensive Training
- Where
- 3 sites in China
- Volunteers
- 236 people
- Sponsor
- Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
Idiopathic Pulmonary Fibrosis
Study of ORJ-001 for the Treatment of IPF
ORJ-001 is a new class of drugs intended for the treatment of patients with idiopathic pulmonary fibrosis (IPF). This is a Phase 2 study in two parts; the objective of Part A will determine if ORJ-001 is well-tolerated by…
- Trial name
- NCT07869147
- Testing
- ORJ-001
- Where
- 2 sites in United States
- Volunteers
- 95 people
- Sponsor
- Oorja Bio, Inc.
Interstitial Lung Disease (ILD), Suspected Interstitial Lung Disease
Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 Trial
The OPTIMIZE-ILD-1 trial is a prospective, randomized, open-label clinical trial designed to evaluate the impact of a coordinated diagnostic pathway on patients with suspected interstitial lung disease (ILD).
- Conditions
- Interstitial Lung Disease (ILD), Suspected Interstitial Lung Disease, Fibrotic Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis (IPF)
- Trial name
- OPTIMIZE-ILD-1 (NCT07482917)
- Testing
- Standard ILD Diagnostic Pathway, Optimized ILD Diagnostic Circuit
- Where
- Spain
- Volunteers
- 92 people
- Sponsor
- Hospital de Granollers
Interstitial Lung Disease Due to Systemic Disease (Disorder), Interstitial Lung Disease Due to Systemic Disease (Telomere Biology Disorder)
Occupational and Environmental Exposures Analysis in Interstitial Lung Diseases.
The OCEAN-ILD study is designed to prospectively evaluate the prevalence and clinical relevance of environmental and occupational exposures in a large Italian cohort of patients affected by any ILD, using a standardised exposure…
- Conditions
- Interstitial Lung Disease Due to Systemic Disease (Disorder), Interstitial Lung Disease Due to Systemic Disease (Telomere Biology Disorder), Exposure Occupational, Occupational Exposure
- Trial name
- OCEAN-ILD (NCT07577115)
- Testing
- standard interview
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- Istituto Clinico Humanitas
Idiopathic Pulmonary Fibrosis
Changes in iOS in IPF
Idiopathic pulmonary fibrosis (IPF) is a condition where scar tissue (called fibrosis) builds up in the lungs. It usually gets worse over time.
- Trial name
- NCT04572958
- Where
- United Kingdom
- Volunteers
- 132 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SRN001 in Healthy Korean and Caucasian Adult Males
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of SRN001 in healthy adult volunteers.
- Trial name
- NCT07407543
- Testing
- SRN001, 0.9% sodium chloride (normal saline)
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- siRNAgen Therapeutics Inc.
Idiopathic Pulmonary Fibrosis
SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
Evaluating Sufenidone (SC1011) in IPF patients for efficacy and safety. Includes screening, treatment, and follow-up, with FVC decline and health checks.
- Trial name
- NCT06125327
- Testing
- SC1011
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Guangzhou JOYO Pharma Co., Ltd
Idiopathic Pulmonary Fibrosis, Mechanical Ventilation Pressure High
End-expiratory Trans-pulmonary Pressure Guided PEEP Titration in Patients With Pulmonary Fibrosis and UIP Pattern Undergoing Mechanical Ventilation
Patients with pulmonary fibrosis and associated usual interstitial pneumonia that require mechanical ventilation for acute respiratory failure experience poor clinical outcomes.
- Trial name
- ETROPON (NCT05098717)
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- University of Modena and Reggio Emilia